Zentalis Pharmaceuticals (ZNTL) Current Assets (2019 - 2026)

Zentalis Pharmaceuticals' Current Assets history runs 8 years deep, the most recent figure standing at $218.1 million for Q1 2026.

• In Q1 2026, Current Assets fell 36.39% year-over-year to $218.1 million; the TTM figure through Mar 2026 stood at $218.1 million (down 36.39% YoY), while the FY2025 annual figure was $253.2 million, down 34.42% from the prior year.
• Current Assets for Q1 2026 stood at $218.1 million, down from $253.2 million in the prior quarter.
• The five-year high for Current Assets was $563.9 million in Q2 2023, with the low at $218.1 million in Q1 2026.
• The 5-year median for Current Assets is $410.2 million (2023), against an average of $399.9 million.
• The sharpest annual moves came in 2022 and 2026: Current Assets jumped 80.24% in 2022, then plunged 36.39% in 2026.
• Zentalis Pharmaceuticals' Current Assets stood at $451.9 million in 2022, then advanced by 9.91% to $496.7 million in 2023, then dropped by 22.28% to $386.1 million in 2024, then sank by 34.42% to $253.2 million in 2025, then fell by 13.86% to $218.1 million in 2026.
• Business Quant data shows ZNTL's Current Assets at $218.1 million in Q1 2026, $253.2 million in Q4 2025, and $288.3 million in Q3 2025.